Document Detail


Prophylactic caffeine to prevent postoperative apnea following general anesthesia in preterm infants.
MedLine Citation:
PMID:  11687065     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Growing ex-preterm infants who undergo general anesthesia for surgery at about term-equivalent age may have episodes of apnea, cyanosis and bradycardia during the early postoperative period. A breathing stimulant such as caffeine, given at the time of operation, might prevent these episodes.
OBJECTIVES: In ex-preterm infants who undergo general anesthesia for surgery, does the prophylactic use of caffeine prevent episodes of apnea, cyanosis and bradycardia during the postoperative period without clinically important side effects?
SEARCH STRATEGY: The standard strategy of the Neonatal Review Group was used. This included searches of the Oxford Database of Perinatal trials, MEDLINE (1966 - July 2001), EMBASE 1980 - July 2001), CINAHL (1982 - July 2001) and Cochrane Library Issue 2, 2001. Search terms included text 'apnea', 'caffeine' and MeSH 'infant, premature'. Searches were also made of previous reviews including cross references. Abstracts of the Society for Pediatric Research were hand searched for the years 1996 - 2001 inclusive.
SELECTION CRITERIA: All trials utilising random or quasi-random patient allocation, in which treatment was compared with placebo or no treatment, were included.
DATA COLLECTION AND ANALYSIS: The standard methods of the Cochrane Collaboration and its Neonatal Review Group were used to select trials, evaluate quality and to extract data. The methodological quality of each trial was reviewed by the second author blinded to trial authors and institution(s). Each author extracted data separately, compared and resolved differences. Meta-analysis used relative risk and risk difference.
MAIN RESULTS: Three eligible trials were found. In each trial apnea/bradycardia occurred in fewer treated than control infants. The typical estimate for relative risk reduction was 91%, 95% CI 66%, 98%. Absolute risk reduction was 58%, indicating that fewer than two infants have to be treated with caffeine to expect to prevent one with postoperative apnea. In two trials continuous recordings of oxygen saturation detected hypoxaemic episodes (<90 %) in fewer treatment than control infants. No infant in any trial required intubation and mechanical ventilation. No adverse effects were reported.
REVIEWER'S CONCLUSIONS: Implications for practice. Caffeine can be used to prevent postoperative apnea/bradycardia and episodes of oxygen desaturation in growing preterm infants if this is deemed clinically necessary. In view of the small numbers of infants studied in these trials and uncertainty concerning the clinical significance of the episodes, caution is warranted in applying these results to routine clinical practice. Implications for research. There is a need to determine which infants might benefit most by this treatment. Studies confined to those most at risk of apnea (prior history, younger postmenstrual age) and those that might require mechanical ventilation (chronic lung disease) would be of value.
Authors:
D J Henderson-Smart; P Steer
Related Documents :
8233715 - The relationship between bradycardia, apnea, and hypoxemia in preterm infants.
6835755 - Infant apnea: polygraphic studies and follow-up monitoring.
9836035 - Apnea following spinal anaesthesia in two former pre-term infants.
10796115 - Doxapram versus methylxanthine for apnea in preterm infants.
15519895 - Maternal exposure to biomass smoke and reduced birth weight in zimbabwe.
19914445 - Cystic fibrosis foundation evidence-based guidelines for management of infants with cys...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The Cochrane database of systematic reviews     Volume:  -     ISSN:  1469-493X     ISO Abbreviation:  Cochrane Database Syst Rev     Publication Date:  2001  
Date Detail:
Created Date:  2001-11-05     Completed Date:  2002-04-19     Revised Date:  2013-06-28    
Medline Journal Info:
Nlm Unique ID:  100909747     Medline TA:  Cochrane Database Syst Rev     Country:  England    
Other Details:
Languages:  eng     Pagination:  CD000048     Citation Subset:  IM    
Affiliation:
NSW Centre for Perinatal Health Services Research, Queen Elizabeth II Institute for Mothers and Infants, Building DO2, University of Sydney, Sydney, NSW, Australia, 2006. dhs@perinatal.usyd.edu.au
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anesthesia, General / adverse effects*
Apnea / etiology,  prevention & control*
Caffeine / therapeutic use*
Central Nervous System Stimulants / therapeutic use*
Humans
Infant, Newborn
Infant, Premature
Infant, Premature, Diseases / prevention & control*
Postoperative Complications / prevention & control*
Postoperative Period
Chemical
Reg. No./Substance:
0/Central Nervous System Stimulants; 58-08-2/Caffeine
Comments/Corrections
Update Of:
Cochrane Database Syst Rev. 2000;(2):CD000048   [PMID:  10796287 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Betamimetics for suspected impaired fetal growth.
Next Document:  Danazol for pelvic pain associated with endometriosis.